Perception of disease, dyadic coping and the quality of life of oncology patients in the active treatment phase and their life partners: Study protocol of an approach based on the actor–partner interdependence model

Abstract Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders (<50% decrease in clinician-rated depression) were treated with adjunctive aripiprazole for 8 weeks (n=97); responders continued escitalopram (n=82). A repeated-measures ANOVA evaluated change in Quality of Life Enjoyment and Satisfaction Short Form scores. QoL was described relative to normative benchmarks. Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.

Download Full-text

Telerehabilitation Intervention in Patients with COVID-19 after Hospital Discharge to Improve Functional Capacity and Quality of Life. Study Protocol for a Multicenter Randomized Clinical Trial

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18062924 ◽

2021 ◽

Vol 18 (6) ◽

pp. 2924

Author(s):

José-Manuel Pastora-Bernal ◽

María-José Estebanez-Pérez ◽

Guadalupe Molina-Torres ◽

Francisco-José García-López ◽

Raquel Sobrino-Sánchez ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Hospital Discharge ◽

Study Protocol ◽

Functional Capacity ◽

Treatment Method ◽

Current Evidence ◽

Current Standard

COVID-19 can cause important sequels in the respiratory system and frequently presents loss of strength, dyspnea, polyneuropathies and multi-organic affectation. Physiotherapy interventions acquire a fundamental role in the recovery of the functions and the quality of life. Regarding the recovery phases after hospital discharge, the current evidence available is very preliminary. Telerehabilitation is presented as a promising complementary treatment method to standard physiotherapy. The main objective of this research is to evaluate the effectiveness of a personalized telerehabilitation intervention after discharge from hospital for the improvement of functional capacity and quality of life compared to a program of health education and/or care in a rehabilitation center. As secondary objectives, to identify the satisfaction and perception of patients with the telerehabilitation intervention and the presence of barriers to its implementation, as well as to evaluate the cost-effectiveness from the perspective of the health system. This study protocol will be carried out through a single blind multicenter randomized clinical trial in the south of Spain. We hypothesize that the implementation of a telerehabilitation program presents results not inferior to those obtained with the current standard intervention. If the hypothesis is confirmed, it would be an opportunity to define new policies and interventions to address this disease and its consequences. Trial registration NCT04742946.

Download Full-text

P.088 The quality of life in oncology patients

Journal of Cranio-Maxillofacial Surgery ◽

10.1016/s1010-5182(08)71876-6 ◽

2008 ◽

Vol 36 ◽

pp. S190

Author(s):

A. Pradillos ◽

S. Bescos ◽

J. Pamias ◽

Ja. Hueto ◽

G. Raspall

Keyword(s):

Quality Of Life ◽

Oncology Patients

Download Full-text

Association between Mutuality and Health-Related Quality of Life in Patient–Caregiver Dyads Living with Schizophrenia

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18052438 ◽

2021 ◽

Vol 18 (5) ◽

pp. 2438

Author(s):

Chiu-Yueh Hsiao ◽

Huei-Lan Lu ◽

Yun-Fang Tsai

Keyword(s):

Quality Of Life ◽

Critical Role ◽

Health Related Quality ◽

Dyadic Relationship ◽

Cross Sectional ◽

Actor Partner Interdependence Model ◽

Related Quality ◽

Health Related ◽

Partner Effect

Background: Although caregivers are a crucial support in the recovery of patients with schizophrenia, little is known about how mutuality is related to health-related quality of life within the dyadic (patient and caregiver) context. This study aimed to investigate the dyadic relationship between mutuality and health-related quality of life in patients with schizophrenia and caregivers. Methods: A cross-sectional, correlational study was conducted with a sample of 133 dyads of patients with schizophrenia and caregivers. Structured questionnaires were used to collect data. Data were analyzed using descriptive statistics, paired sample t-tests, Pearson’s product-moment correlations, and the Actor–Partner Interdependence Model. Results: Mutuality of patients was significantly higher than that of caregivers. Compared with caregivers, patients had significantly lower total scores for health-related quality of life. Patients’ and caregivers’ mutuality was related to their own health-related quality of life (actor effect) and their partners’ health-related quality of life (partner effect). Conclusion: Mutuality plays a critical role in health-related quality of life in dyads of patients with schizophrenia and caregivers. Viewing a dyad as a unit of nursing care reveals a promising approach for developing recovery-oriented modalities targeted at stimulating mutuality that may enhance health-related quality of life for both patients and caregivers.

Download Full-text

Mobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers

BMJ Open ◽

10.1136/bmjopen-2017-021346 ◽

2018 ◽

Vol 8 (7) ◽

pp. e021346 ◽

Cited By ~ 5

Author(s):

Anna Alonso-Solís ◽

Katya Rubinstein ◽

Iluminada Corripio ◽

Erika Jaaskelainen ◽

Annika Seppälä ◽

...

Keyword(s):

Quality Of Life ◽

European Union ◽

Feasibility Study ◽

Study Protocol ◽

Preliminary Data ◽

Perceived Quality ◽

The European Union ◽

Treatment Resistant ◽

Perceived Quality Of Life

IntroductionTreatment-resistant schizophrenia (TRS) is a severe form of schizophrenia. In the European Union, approximately 40% of people with schizophrenia have TRS. Factors such as the persistence of positive symptoms or higher risk of comorbidities leave clinicians with a complex scenario when treating these patients. Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Mobile therapeutic attention for treatment-resistant schizophrenia(m-RESIST), an innovative mHealth solution based on novel technology and offering high modular and flexible functioning, has been developed specifically for patients with TRS and their caregivers. As intervention in TRS is a challenge, it is necessary to perform a feasibility study before the cost-effectiveness testing stage.Methods and analysisThis manuscript describes the protocol for a prospective multicentre feasibility study in 45 patients with TRS and their caregivers who will be attended in the public health system of three localities: Hospital Santa Creu Sant Pau (Spain), Semmelweis University (Hungary) and Gertner Institute & Sheba Medical Center (Israel). The primary aim is to investigate the feasibility and acceptability of the m-RESIST solution, configured by three mHealth tools: an app, wearable and a web-based platform. The solution collects data about acceptability, usability and satisfaction, together with preliminary data on perceived quality of life, symptoms and economic variables. The secondary aim is to collect preliminary data on perceived quality of life, symptoms and economic variables.Ethics and disseminationThis study protocol, funded by the Horizon 2020 Programme of the European Union, has the approval of the ethics committees of the participating institutions. Participants will be fully informed of the purpose and procedures of the study, and signed inform consents will be obtained. The results will be published in peer-reviewed journals and presented in scientific conferences to ensure widespread dissemination.Trial registration numberNCT03064776; Pre-results.

Download Full-text